AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
CNBC
Read Full Article at CNBC →Ad Slot — In-Article (728x90)
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
This is a summary. For the full story, read the original article at CNBC.
Original source: CNBC